ITIL-306 in Advanced Solid Tumors
Phase 1 Terminated
1 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Phase 1 Terminated
4 enrolled
CONTACT-03
Phase 3 Terminated
522 enrolled 22 charts
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 1/2 Terminated
42 enrolled
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Phase 1 Terminated
40 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
TEM-GU
Phase 1/2 Terminated
10 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 Terminated
120 enrolled
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Phase 2 Terminated
18 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2 Terminated
6 enrolled 7 charts
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
9 enrolled
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1 Terminated
85 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
Study of INCB086550 in Select Solid Tumors
Phase 2 Terminated
16 enrolled 17 charts
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Terminated
106 enrolled 21 charts
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Phase 1 Terminated
19 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
TRANSLATE
Phase NA Terminated
38 enrolled 17 charts
PRETZCEL
Phase 2 Terminated
3 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Phase 1/2 Terminated
66 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Phase 1 Terminated
3 enrolled
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
OPTIMISE
Terminated
77 enrolled 34 charts
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Study of PY314 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
86 enrolled
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Phase 1 Terminated
35 enrolled
TRACE
Terminated
246 enrolled 18 charts
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase 1/2 Terminated
252 enrolled 67 charts
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase 1/2 Terminated
72 enrolled
Vaccine Therapy in Treating Patients With Kidney Cancer
Phase 1 Terminated
9 enrolled
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Terminated
20 enrolled